Charles River Laboratories Q3 2026: Safety Demand Drives Guidance Hike

Charles River Laboratories posted adjusted non-GAAP EPS of $3.09 for the third quarter of 2026, topping the consensus estimate of $2.97 and extending the company's streak of beating EPS expectations to six consecutive quarters. Revenue came in at $982.7 million, clearing the $960.4 million estimate. The beat marked a meaningful inflection after several quarters of muted growth.

The Discovery and Safety Assessment segment drove the outperformance, with organic revenue up 5.9%, fueled by higher volumes for regulated safety assessment services and lower sourcing costs for large research models. That momentum translated into a non-GAAP operating margin for the DSA unit of 26.8%, while the company's overall non-GAAP operating margin expanded to 23.0%, up 330 basis points, partly because shedding the lower-margin CDMO and Cell Solutions businesses in May 2026 cleaned up the portfolio mix.

Reported sales fell 2.2% year over year, almost entirely because of those May divestitures, so the headline revenue number understates underlying momentum. Organic revenue across the whole company grew 4.7%, with Manufacturing Solutions contributing 7.4% organic growth and DSA adding 5.9%. The Research Models and Services segment was a drag, with reported revenue down 2.8%, weighed down by lower North American small and large research model revenue.

GAAP diluted EPS came in at $6.86, inflated by a $245.6 million reversal of acquired tax reserves tied to newly enacted foreign tax legislation, a one-time item the company excluded from its non-GAAP results. Management was careful to strip that out when updating guidance, raising full-year non-GAAP EPS guidance to $11.35 to $11.55 from a prior range of $11.15 to $11.45. The company also lifted its organic revenue growth outlook to at least 1.5%, up from a prior range of 0.0% to 1.0%.

CEO Birgit Girshick pointed to DSA net bookings and proposals showing robust year-over-year increases as evidence that the demand recovery has legs beyond a single quarter. The company's Pathway to Purpose strategy, unveiled at its 2026 Investor Day, is aimed at deepening client relationships and capturing a larger share of R&D spend as biopharmaceutical outsourcing trends continue to improve. Investors will want to track whether that bookings momentum converts to revenue in the quarters ahead, particularly as the company absorbs restructuring and efficiency costs now expected to run about $1.50 per share for the full year.